Abstract: Whereas GLP-1 medicines like Ozempic, Wegovy, and Zepbound have revolutionized weight problems therapy, the outcomes are famously inconsistent—some sufferers lose 20% of their physique weight whereas others battle to hit 5%.
A landmark research has recognized the genetic foundation for this “trial and error” actuality. By analyzing practically 28,000 people, researchers pinpointed particular variants within the GLP1R and GIPR genes that act as organic dials, figuring out each the velocity of weight reduction and the severity of unintended effects like nausea and vomiting.
Key Details
- The “Tremendous-Responder” Variant: A selected missense variant within the GLP1R gene (rs10305420) was linked to considerably larger weight reduction—carriers misplaced about 0.76 kg (1.6 lbs) extra per allele than non-carriers.
- Facet Impact Signaling: The research recognized that nausea and vomiting aren’t simply “unhealthy luck”; they’re linked to variations within the very genes the medicine goal.
- Tirzepatide Specificity: A variant within the GIPR gene was discovered to foretell nausea particularly for customers of tirzepatide (Mounjaro/Zepbound) however not semaglutide. It’s because tirzepatide targets each GLP-1 and GIP receptors.
- Broad Spectrum of Danger: Relying on genetics and scientific components, a affected person’s likelihood of experiencing nausea or vomiting can vary from a manageable 5% to a debilitating 78%.
- Precision Weight problems Instrument: 23andMe has built-in these findings into its Complete Well being service, permitting members to make use of an interactive device to estimate their private weight reduction (6% to twenty%) and facet impact threat earlier than beginning therapy.
Supply: 23andMe Analysis
GLP-1 receptor agonists, together with semaglutide and tirzepatide, have reworked the scientific administration of weight and weight problems. Nonetheless, sufferers expertise substantial variability in each weight reduction efficacy and the incidence of unintended effects.
Some people lose lower than 5% of their physique weight, whereas others lose greater than 20%. Some people expertise unintended effects comparable to nausea and vomiting, whereas others don’t.
Printed at the moment in Nature, the research investigates the genetic foundation of this variability. Researchers at 23andMe performed a large-scale genome-wide affiliation research (GWAS) using knowledge from 27,885 people who’ve used GLP-1 medicines.
The findings present direct proof that variation within the genes focused by GLP-1 medicines contribute to why folks reply otherwise to GLP-1 therapies.
“The research demonstrates the unimaginable energy of our crowdsourced analysis neighborhood to advance scientific understanding of human genetic variation,” mentioned Adam Auton, Vice President of Human Genetics at 23andMe Analysis Institute and an creator of the research.
By analyzing each genetic markers and self-reported affected person experiences, the analysis crew uncovered a number of key insights into how human genetics affect the results of those broadly prescribed medicines:
- Weight Loss: Researchers recognized a missense variant, a small change in a gene sequence that alters the protein it makes, within the GLP1R gene that’s considerably related to elevated efficacy of GLP-1 medicines.
- Nausea and Vomiting: The research recognized associations linking variation in each the GLP1R and GIPR genes to GLP-1 medication-related nausea or vomiting.
- Drug-Particular Results: The affiliation between the GIPR genetic variation and nausea and vomiting unintended effects is restricted particularly to people utilizing tirzepatide (Mounjaro© and Zepbound©), and never semaglutide (Ozempic© and Wegovy©).
These discoveries lay the muse for extra customized approaches within the therapy of weight problems, suggesting a future the place genetic testing may assist information therapy methods.
The 23andMe analysis crew efficiently included these findings right into a broader mannequin of GLP-1 medicine response that features demographic and scientific components, demonstrating the flexibility to stratify sufferers by each weight reduction efficacy and threat for sure unintended effects.
The group has launched a brand new report, known as GLP-1 Drugs Weight Loss and Nausea, to members of its Complete Well being service. The brand new report offers perception into weight reduction and nausea threat when taking a GLP-1 medicine primarily based on these new findings from 23andMe analysis.
This new report consists of an interactive device that permits people to discover how genetics and different components like age and sure medical situations could influence weight reduction and nausea on GLP-1 medicines. Collectively, these components can predict important variability in a person’s probability of weight reduction or unintended effects.
Amongst 23andMe analysis individuals, weight reduction estimates differ between 6% and 20% of beginning weight, and the possibilities of nausea or vomiting vary from 5% to 78%, relying on genetics and different components.
The brand new GLP-1 Drugs: Weight Loss and Nausea report is solely out there by way of 23andMe’s Complete Well being service, which incorporates clinician steerage. Complete Well being Studies are reviewed by clinicians and supposed to be used in a supervised scientific context.
“Whereas there may be excessive curiosity in GLP-1 medicines, there may be important variation in how nicely they work for various folks. The market is crowded with weight reduction help and medicines, however the method to weight administration is often one in every of trial and error. This will lead folks to leap into therapy with a excessive diploma of uncertainty and unrealistic expectations about efficacy and doable unintended effects, mentioned Dr. Noura Abul-Husn, MD, PhD, Chief Medical Officer on the 23andMe Analysis Institute.
“We imagine these experiences are a step ahead in assembly an unmet want for a extra knowledgeable and customized method to weight administration.”
“The brand new GLP-1 report is part of our Complete Well being service, the place a clinician is a part of the dialog,” continued Abul-Husn.
“GLP-1 therapy choices are complicated and accessing scientific experience to assist contextualize your genetic outcomes alongside your full well being image is strictly the type of steerage this report is designed to help.”
Key Questions Answered:
A: Not precisely. Whereas the GLP1R variant will increase your “effectivity,” genetics is just one a part of the puzzle. Components like your beginning weight, age, food regimen, and drug dose nonetheless play the dominant position. Consider the gene as a “tailwind”—it makes the journey simpler, however you continue to should steer the ship.
A: Semaglutide (Ozempic/Wegovy) is a “monotherapy” that solely targets the GLP-1 receptor. Tirzepatide (Zepbound/Mounjaro) is a “dual-agonist” that targets each GLP-1 and GIP. As a result of it’s hitting that second goal, variations within the GIP receptor gene straight influence how the physique reacts to that particular drug.
A: It could’t make a “sure/no” determination, however it might probably present a “heads up.” In case your genetics put you within the 78% threat class for vomiting, you and your physician may select to start out at an ultra-low dose or prioritize a unique weight-management technique to keep away from a depressing expertise.
Editorial Notes:
- This text was edited by a Neuroscience Information editor.
- Journal paper reviewed in full.
- Further context added by our workers.
About this genetics and weight reduction analysis information
Writer: Catherine Afarian
Supply: 23andMe Analysis
Contact: Catherine Afarian – 23andMe Analysis
Picture: The picture is credited to Neuroscience Information
Authentic Analysis: Open entry.
“Genetic predictors of GLP1 receptor agonist weight reduction and unintended effects” by Qiaojuan Jane Su, James R. Ashenhurst, Wanwan Xu, Vinh Tran, R. Ryanne Wu, Catherine H. Weldon, Jingchunzi Shi, Barry Hicks, 23andMe Analysis Crew, Noura S. Abul-Husn, Stella Aslibekyan, Michael V. Holmes, Bertram L. Koelsch & Adam Auton. Nature
DOI:10.1038/s41586-026-10330-z
Summary
Genetic predictors of GLP1 receptor agonist weight reduction and unintended effects
The event of glucagon-like peptide 1 (GLP1) receptor agonists, together with semaglutide and tirzepatide, has reworked the scientific administration of chubby and weight problems. Nonetheless, substantial inter-person variability exists in each weight reduction efficacy and the incidence of unintended effects.
To analyze the genetic foundation of this variability, right here we conduct a genome-wide affiliation research of self-reported weight reduction and treatment-related unintended effects in 27,885 folks following GLP1 receptor agonist remedy.
We establish a missense variant in GLP1R that’s related considerably with elevated efficacy of GLP1 medicines (P = 2.9 × 10−10), with an extra −0.76 kg of weight reduction anticipated per copy of the impact allele.
Moreover, we establish associations linking variation in each GLP1R and GIPR to GLP1 medication-related nausea or vomiting, with the GIPR affiliation being restricted to folks utilizing tirzepatide.
We incorporate these findings right into a broader mannequin of GLP1 medicine response, and show the flexibility to stratify sufferers by efficacy and facet impact threat.
These findings present direct genetic proof that variation within the drug goal genes contributes to inter-person variability in response and lay the muse for precision medication approaches within the therapy of weight problems.
